Champions Oncology, Inc.
CSBR · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.5% | -6.9% | 9.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 47.3% | 41.4% | 45.2% | 51.9% |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 11.1% | -10.8% | -3.8% | 6.1% |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 8.3% | -14.5% | -9.9% | 1.1% |
| EPS Diluted | 0.33 | -0.54 | -0.39 | 0.039 |
| % Growth | 161.1% | -38.5% | -1,107.8% | – |
| Operating Cash Flow | $0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | $0 |